Freshly isolated human neutrophils were investigated for their ability to degrade heparan sulfate proteoglycans in the subendothelial extracellular matrix (ECM) produced by cultured corneal and vascular endothelial cells. The ECM was metabolically labeled with Na2(35S)04 and labeled degradation products were analyzed by gel filtration over Sepharose 6B. More than 90% of the released radioactivity consisted of heparan sulfate fragments 5-6 times smaller than intact heparan sulfate side chains released from the ECM by either papain or alkaline borohydride. These fragments were sensitive to deamination with nitrous acid and were not produced in the presence of either heparin or serine protease inhibitors. In contrast, degradation of soluble high molecular weight heparan sulfate proteoglycan, which was first released from the ECM, was inhibited by heparin but there was no effect of protease inhibitors. These results indicate that interaction of human neutrophils with the subendothelial ECM is associated with degradation of its heparan sulfate by means of a specific, newly identified, heparanase activity and that this degradation is facilitated to a large extent by serine proteases.
Introduction
Neutrophil mobilization constitutes an early and important event in the acute inflammatory process. On their way from the blood toward an affected tissue the cells must invade across the endothelium of postcapillary venules and the underlying basal lamina (1) . This process involves adherence of neutrophils to the endothelial luminal surface, invasion and dissociation of endothelial cell junctions, and active participation of hydrolytic enzymes (2, 3) . The same is true for virtually every epithelium in the body that is traversed by human neutrophils before they accumulate at the site of inflammation (4) . Cell migration is thought to be driven by a chemotactic factor(s) gradient, which at the infected area, is high enough to induce discharge ofgranules and a subsequent 0°production (5) . In contrast, while still in circulation the cells exhibit little or no enzyme release in response to the low concentration of the chemoattractant, and thus the vascular endothelial cell lining is protected. It was therefore postulated that neutrophils may contain an additional distinct secretory compartment whose enzymes are excreted in response to a threshold signal, and may participate in the early events of neutrophil mobilization and diapedesis without damaging the endothelial cells themselves. Such a role has been recently ascribed to a metallo-proteinase (gelatinase) that is preferentially released from human neutrophils even in the absence of added stimuli (6) .
Recent research on degradation of extracellular macromolecules by invasive cells, whether normal or malignant, has emphasized the use of complex, naturally produced substrates because these resemble the in vivo situation better than isolated constituents of the extracellular matrix (ECM)' (7) (8) (9) . Such a substrate is the subendothelial ECM deposited by cultured bovine endothelial cells (10, 1 1) . This ECM has been shown to resemble the vascular basement membrane in its morphological appearance, platelet reactivity (12), and supramolecular arrangement and to contain characteristic constituents such as laminin, fibronectin, collagen types III and IV, and heparan sulfate (10) (11) (12) (13) (14) . Proline-labeled matrices secreted by cultured venous endothelial cells were shown to be rapidly degraded by triggered neutrophils via a process dependent on elastase but not oxygen metabolites ( 15) . Other studies on the interaction of cells with the subendothelial ECM revealed a correlation between the activity of a heparan sulfate degrading endoglycosidase (heparanase) and the metastatic potential of various mouse melanoma (16) and lymphoma (17) sublines. The enzyme has also been suggested as playing a role in the extravasation and homing of activated lymphocytes (18, 19) and macrophages (18) and to degrade heparan sulfate upon interaction of platelets with the endothelial cell surface (20) and subendothelial ECM (12).
The present study was Fractions were counted for radioactivity using Bio-fluor scintillation fluid.
The excluded volume (V.) was marked by blue dextran, and the total included volume (V,) by phenol red. The latter was shown to co-migrate with free (35S)O; (17) (18) (19) Biochemical assays. Lysozyme (26) , lactate dehydrogenase (26) , and proteolysis of 14C-globin (22) were determined by previously published methods.
Results
Degradation ofsulfated proteoglycans in the ECM by the neutrophil heparanase. Human neutrophils suspended in RPMI medium adhered to the subendothelial ECM within 30 min after seeding. -30% ofthe cells attached firmly to the ECM, adopted a flattened and slightly elongated morphology, and showed filopodia and well developed ruffles in contact with the ECM. The other cells were either loosely attached or floating. Only 10-15% of the cells were firmly attached at 24 h after seeding but >95% of the entire cell population remained viable as determined by the trypan blue exclusion test. Degradation of sulfated macromolecules in the ECM was studied by allowing the cells to interact with sulfate-labeled ECM followed by gel filtration (Sepharose 6B) analysis of degradation products released into the incubation medium. In the presence of medium alone (RPMI + 10% FCS) there was a constant release of labeled material (30% ofthe total incorporated radioactivity over 24 h) that consisted almost entirely (>90%) oflarge Mr (peak I) components eluted with or next to V. (14, 17) . In contrast, as demonstrated in Fig. 1 5 X 106 neutrophils suspended in 1 ml RPMI medium containing 10% FCS were incubated (24 h, 370C), pH 6.3, in contact with sulfatelabeled ECM in the absence (-) and presence (A) of 10 ug/ml heparin.
The medium was collected, centrifuged, and analyzed by gel filtration on Sepharose 6B as described in Methods. (5 X 106 cells/35-mm dish) suspended in RPMI medium and 10% FCS (pH 6.3) resulted in a release of low Mr labeled material (peak II, Kav -0.68), which constituted >80% of the total released radioactivity. Low Mr material released from the ECM and eluted as peak II was detected already after 1 h incubation with the cells. Its amount increased progressively as time proceeded and reached a plateau at 24 h. -70% of the total ECM incorporated sulfate was released during a 24-h incubation with 5 X 106 neutrophils. Release of low Mr (peak II) degradation products was inhibited in the presence of 10 tg/ml heparin ( Fig.   1 ) or when the pH of the incubation medium was higher than 7.2 (not shown). Under these conditions 80-90% ofthe released radioactivity was eluted from Sepharose 6B with and next to VO (0.1 < Kav < 0.3). Exposure ofthe ECM to papain (0.2 mg/ml, 24 h, 50'C) or alkaline borohydride (1 M NaBH4 in 0.05 N NaOH, 24 h, 450C) (27) resulted in a release ofintact glycosaminoglycan side chains eluted with a Kav of 0.35 (17) . This value corresponds to a Mr of about 45,000 daltons (28) which is fiveto sixfold higher than that of fragments released during incubation of the ECM with the human granulocytes (Kav -0.68; Mr -8.5 X 103 D). The latter were shown to be degradation products of heparan sulfate as indicated by their resistance to chondroitinase ABC and papain digestion, sensitivity to deamination with nitrous acid (27) (Fig. 2) , and precipitation of 70-80% of the released radioactivity with 0.05% CPC in 0.6 M NaCl (29) (not shown). The extent of ECM heparan sulfate degradation was not affected by the presence of either zymosan activated serum (10% vol/vol) or phorbol myristate acetate (100 ng/ml). There was also no significant effect to first "charging" the labeled ECM by incubation with these chemoattractants followed by washing the unbound material before incubation with the neutrophils.
Release ofheparanase activity. Heparanase activity is secreted by highly metastatic sublines of mouse lymphoma (16) and melanoma (17) cells and by activated lymphocytes (18, 19) and macrophages (18) . As demonstrated in Fig. 2 , incubation of freshly isolated human neutrophils (5 X 106 cells/ml PBS) for 1 h at 4°C resulted in a release of heparanase activity as detected by degradation of sulfate-labeled ECM upon incubation with a low-speed (300 g, 10 min) supernate fraction ofthe preincubated neutrophils. Similar results were obtained regardless ofthe presence or absence of calcium and magnesium in the PBS. Heparan sulfate degradation manifested by the appearance ofpeak II material was already observed after 3 h of incubation (37°C, pH 6.2) ofthe labeled ECM with I ml ofthe 4°C supernate fraction and reached a maximal value at 24 h ( Fig. 3 B) . Heparanase activity was detected upon incubation (24 h, 37°C, pH 6.2) of the ECM with as little as 0.1 ml of this neutrophil supernatant (Fig. 3 A) and was inhibited in the presence of heparin (Fig. 2) . Incubation of ECM with PBS alone yielded small amounts (<10% ofthe total incorporated radioactivity) of labeled material eluted at V. but no material eluted as peak II. -90% of the (Fig. 4) . The heparan sulfate nature of these fragments was confirmed by exposing the labeled material eluted as peak II to nitrous acid (0.24 M NaNO3 in 1.8 M acetic acid, 80 min, 240C) (27) . This resulted in further cleavage to low M, (2.5 X 103 D) fragments that were not precipitated by CPC, were eluted with a Kav of 0.84 from Sepharose 6B (Fig. 2) , and were retarded on Sephadex G-50.
By using our semiquantitative ECM degradation assay and testing various dilutions of both the 4VC supernate fraction and of lysed preparations of the resuspended cell pellet, it was estimated that 20-25% of the total cellular content of ECM-heparan sulfate degrading activity was released during the 1-h incubation of neutrophils at 40C (Fig. 5 , Table I ). Under the conditions of these experiments <50% of the total incorporated radioactivity was released from the ECM and the amount of labeled material eluted as peak II was proportional to the amount of heparanase added. Table I shows that only 3-6% of the cellular content of lysozyme and globin degrading proteases (22) were released into the 4°C supernate fraction. Moreover, release was not due to cell damage since the cytoplasmic enzyme lactate dehydrogenase was fully retained (Table I ). In the above estimation ofpercentage enzyme release it is assumed that the activity of the various enzymes is not affected by cell disruption or affected to a similar extent with all enzymes. 30-min incubation of neutrophils at Partial purification of heparanase activity. Because of the preferential release of heparanase activity, we attempted to further purify the enzyme from the 4°C neutrophil supernate fraction. For this purpose, human neutrophils were isolated from 400 ml normal human blood and suspended in 100 ml of PBS containing Ca2' and Mg2'. After 1-h incubation at 4°C, the supernate fraction was filtered through a heparin-Sepharose column (1.6 X 5 cm). As shown in Fig. 6 , both the unadsorbed material and subsequent elution of the column with 0.45 M NaCl (100 ml) had no detectable heparanase activity. The column was then eluted with 1 M NaCI (20 ml in 2-ml fractions) and the material eluted in fractions 3-5 showed a six-to 10-fold higher heparanase activity per milliliter as compared with the original 4°C supernate fraction. The amount of protein in both the starting material and active fractions was too low for an accurate determination by absorbance at 280 nm or by the dye fixation (Bradford) assay. Preliminary analysis by NaDodSO4 polyacrylamide gel electrophoresis and silver nitrate staining revealed, in some of the active fractions, a single faint band with an apparent molecular weight of -80,000 (not shown). Sequential degradation ofECM-bound heparan sulfate proteoglycan by a protease followed by heparanase. Exposure of sulfate-labeled ECM to the 4VC supernate fraction of human neutrophils at pH 8.0 resulted in a release of high Mr labeled material eluted as a broad peak (fractions 10-35) next to V. (Fig.   7) . A similar elution profile was obtained after exposure (12 h, 370C, pH 8.0) ofthe ECM to proteolytic enzymes such as trypsin, or chymotrypsin (10 ,g/ml) (17) . The broadness of this peak I depended on the enzyme concentration and time of incubation with the ECM, but under no circumstances did such incubation yield fragments smaller than intact heparan sulfate side chains (Kav = 0.35). As demonstrated in Fig. 7 A, (Fig. 8) .
The contributory role of a proteolytic activity was also dt onstrated when degradation ofECM-bound heparan sulfate w. Figure 6 . Partial purification by heparin-Sepharose chromatography of the neutrophil heparanase. Human neutrophils isolated from 400 ml blood were suspended in 100 ml PBS, incubated for 60 min at 40C, and centrifuged (10 min, 300 g). The supernatant was filtered through a heparin-Sepharose column (1.6 X 5 cm) that had been equilibrated with 0.15 M NaCl in 0.01 M sodium acetate-acetic acid (pH 5.5). Fractions of 10 ml were collected during sample loading and column wash with 100 ml of 0.45 M NaCI in 0.01 M acetate buffer (pH 5.5). 1 M NaCl in 0.01 M acetate buffer (pH 5.5) was then added and 10 fractions of 2 ml each were collected. Chromatography was conducted at 40C with flow rates maintained at 25 ml/h. 0.2-ml aliquots of each fraction were diluted with PBS and/or water to a final volume of I ml and to a salt concentration of 0.15-0.2 M. The pH was adjusted to 6.0 and the samples were incubated (24 h, 370C) with sulfate-labeled ECM. Labeled degradation products were analyzed by gel filtration on Sepharose 6B. Unadsorbed material (A) and material eluted with 0.45 M NaCl (A) showed no heparanase activity in all fractions, whether diluted or not, as compared with 0.2 ml of the original 4VC neutrophil supernatant (o) or to 0.2 ml of the I M NaCI eluant (., fraction 3). A progressive decrease in heparanase activity was observed in fractions 4-10 of the 1 M NaCI eluant. attempted with small amounts (0.1-0.25 ml) of the 4VC neutrophil supernate. The addition of trypsin or chymotrypsin to the incubation mixture stimulated three-to fivefold the release of low Mr, heparanase-mediated heparan sulfate degradation fragments, and the released material had a Mr somewhat smaller than that observed in the absence ofthese proteases (not shown). Heparin inhibited both the basal and protease stimulated heparanase activity. In contrast, trypsin had no effect on degradation of soluble heparan sulfate proteoglycan that was first released from the ECM by incubation with the 4VC neutrophil supernatant at pH 8.0 (not shown).
Discussion
We have previously reported that heparanase activity is correlated with the extravasation of lymphocytes (18, 19) and macrophages (18) toward an affected extravascular site. We now show that the ECM heparan sulfate is also degraded by human neutrophils and that the newly identified neutrophil heparanase is preferentially secreted by simply incubating the cells at 4VC without added stimuli. A somewhat similar situation was described for the neutrophil gelatinase where 30-40% ofthe enzyme cellular content was released under mild stimulatory conditions I Figure 7 . Effect of PMSF on degradation of sulfate-labeled ECM by enzymes secreted from neutrophils. Freshly isolated neutrophils suspended in PBS (5 x 106 cells/ml) were incubated at 40C for 60 min. The cells were centrifuged and the supernatant was adjusted to pH 8.0 (A), and 6.2 (B). Supernatants were incubated (24 h, 370C) at these pH values with sulfate-labeled ECM in the absence (A, e) or presence (o) of 5 mM PMSF. 1 ml of the pH 8.0 supernatant was also heated (950C, 10 min) before incubation with the labeld ECM (x). Labeled material released into the incubation medium was applied for gel filtration onto Sepharose 6B columns.
(incubation at 370C of cells that had been stored in the cold for 24 h) (6) . It was proposed that the enzyme is localized within a novel secretory compartment of human neutrophils, and that together with other enzymes stored in this secretory organelle, is involved in the early events of neutrophil mobilization (6 (17) . The high Mr material was then collected and 0.5-ml aliquots were taken for gel filtration (x) or for further incubation (24 h, 37°C) with 0. (16) (17) (18) (19) ). In contrast, the platelet heparitinase was released only in response to a strong stimulus such as thrombin but was retained upon platelet aggregation induced by the ECM (12, 31) . Although with all the cell types tested the low Mr heparan sulfate degradation products seem similar in size, it is not certain whether the same endoglycosidase activity is involved. In fact, different substrate specificities were shown for the platelet and B 16 melanoma enzymes (32) . We serum-free conditioned medium (17) was subjected to heparinSepharose chromatography. Because the ESb-conditioned medium contained 50-100-fold more protein than the 4VC neutrophil supernatant, we could show that >95% ofthe total protein but almost no enzyme activity was eluted while loading the sample and in the 0.45 M NaCl eluant.
As shown with other cell systems (34), degradation of ECMbound heparan sulfate, but not of a soluble heparan sulfate proteoglycan, was facilitated by a proteolytic activity. The presently observed almost complete inhibition of degradation of ECMbound heparan sulfate by protease inhibitors, indicates that under certain conditions a proteolytic digestion of the ECM is a necessary prerequisite for subsequent degradation of heparan sulfate side chains by the neutrophil heparanase. Because the subendothelial ECM contains a number of elastase-sensitive targets including fibronectin, laminin, proteoglycans, and collagens (types I, III, and IV) (35) , such a role can be fulfilled by the neutrophil elastase, which had already been shown to be primarily responsible for matrix degradation by triggered neutrophils (15) . Our studies with the 40C neutrophil supernatant showed that <4% ofthe total cellular content ofglobin degrading proteases was released under conditions that liberated at least 20% of the cellular heparanase content. Nevertheless, this low proteolytic activity was high enough to enable degradation of ECM-bound heparan sulfate by means of the neutrophil heparanase. Thus, degradation of heparan sulfate in the subendothelial ECM is likely to proceed in a sequential manner so that one enzyme (protease) provides a more accessible substrate for the next enzyme (heparanase). Such a combined enzymatic cleavage is characteristic of a supramolecular structure such as the ECM where degradation of a given constituent is affected by its covalent and noncovalent interactions with other components (7). These interactions may stabilize and/or mask the molecule so that it becomes less susceptible to cleavage by specific enzymes. Likewise, studies with the ECM produced by smooth muscle cells have shown that degradation ofelastin and collagen by human sarcoma cells was accelerated by prior treatment of the matrix with plasmin or trypsin to remove connective tissue glycoproteins (36) . It has also been proposed that collagen may serve to limit glycosaminoglycan degradation in the basal lamina (37) .
Heparan sulfate proteoglycans interact with different attachment sites on plasma membranes and with macromolecules such as collagen and fibronectin in the matrix (38) . This suggests a key role for this proteoglycan in the self-assembly and insolubility of the ECM as well as in cell adhesion and locomotion. Studies with various types of blood-borne cells have demonstrated that degradation of heparan sulfate side chains rather than release of the intact proteoglycan is correlated with the ability of cells to extravasate (16) (17) (18) (19) . A possible explanation is that in vivo the released high Mr proteoglycan is likely to be trapped in the tissue due to its size and noncovalent interactions with other extracellular constituents and hence can still create a barrier for cell invasion. In contrast, the low Mr glycosaminoglycan fragments are not restricted by the collagen fiber network and can more readily be cleared from the tissue. Moreover, the removal of glycosaminoglycans from the tissue exposes the collagen network and increases the susceptibility of collagen to cleavage by collagenolytic enzymes (39) .
A fundamental question in the transendothelial migration of leukocytes is their homing to targets outside the vessels. Our studies with specifically activated T lymphocytes ( 19) suggested that ECM-bound antigens may dictate, via activation of ECM degrading enzymes, the site of extravasation and hence the homing of blood-borne cells. Although we could not demonstrate an effect of ECM-bound chemoattractants, the question of whether chemotactic substances sequestered by the ECM of an affected organ play a role in the recruitment of neutrophils to inflammatory sites requires further investigation. The present results with neutrophils, and our previous studies with lymphocytes (18, 19) and macrophages (18) , suggest a mechanism for modulation of heparanase activity and release in response to various signals. On the other hand, blood-borne tumor cells either may exhibit a constitutive expression of the enzyme in correlation with their metastatic potential (16, 17) or can recruit normal cells (macrophages, neutrophils, lymphocytes, and platelets) and capitalize on their ability to infiltrate tissues (40, 41) .
